The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: A pilot study

Respiratory Medicine

Volumn 101, Issue 5, 2007, Pages 957-962

  Cazzola, Mario ^a   Gabriella Matera, Maria ^b  

^a CARDARELLI HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Combination therapy; COPD; Formoterol; Theophylline; Tiotropium

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FORMOTEROL; LONG ACTING DRUG; PLACEBO; SALBUTAMOL; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG USE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL DISEASE; HEART ARRHYTHMIA; HUMAN; INSOMNIA; MALE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT DURATION; VISUAL ANALOG SCALE;

AGED; ALBUTEROL; BRONCHODILATOR AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; DYSPNEA; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES; SINGLE-BLIND METHOD; THEOPHYLLINE; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 33947723601     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2006.09.012     Document Type: Article

References (27)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2005 [accessed August 26, 2006]. Available at: 〈http://www.goldcopd.com〉.
2. Celli B.R., and MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23 (2004) 932-946
3. Cazzola M., Di Marco F., Santus P., Boveri B., Verga M., Matera M.G., et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther 17 (2004) 35-39
4. Cazzola M., Centanni S., Santus P., Verga M., Mondoni M., di Marco F., et al. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med 98 (2004) 1214-1221
5. Cazzola M., Noschese P., Salzillo A., De Giglio C., D'Amato G., and Matera M.G. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. Respir Med 99 (2005) 524-528
6. van Noord J.A., Aumann J.L., Janssens E., Smeets J.J., Verhaert J., Disse B., et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 26 (2005) 214-222
7. van Noord J.A., Aumann J.L., Janssens E., Verhaert J., Smeets J.J., Mueller A., et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 129 (2006) 509-517
8. Tashkin D., Celli B., Decramer M., Burkhart D., Kesten S., and Cassino C. Prescribing patterns according to COPD treatment guidelines in patients enrolled in a global clinical trial [abstract]. Proc Am Thorac Soc 3 (2006) A111
9. 2 agonists and theophylline in stable chronic obstructive pulmonary disease. Thorax 54 (1999) 730-736
10. Cazzola M., Di Lorenzo G., Di Perna F., Calderaro F., Testi R., and Centanni S. Additive effects of salmeterol and fluticasone or theophylline in COPD. Chest 118 (2000) 1576-1581
11. ZuWallack R.L., Mahler D.A., Reilly D., Church N., Emmett A., Rickard K., et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 119 (2001) 1661-1670
12. Barnes P.J. Theophylline in chronic obstructive pulmonary disease: new horizons. Proc Am Thorac Soc 2 (2005) 334-339
13. Kirsten D.K., Wegner R.E., Jorres R.A., and Magnussen H. Effects of theophylline withdrawal in severe chronic obstructive pulmonary disease. Chest 104 (1993) 1101-1107
14. Burge P.S., Calverley P.M., Jones P.W., Spencer S., Anderson J.A., and Maslen T.K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J 320 (2000) 1297-1303
15. Donohue J.F. Combination therapy for chronic obstructive pulmonary disease: clinical aspects. Proc Am Thorac Soc 2 (2005) 272-281
16. Filuk R.B., Easton P.A., and Anthonisen N.R. Responses to large doses of salbutamol and theophylline in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 132 (1985) 871-874
17. Thomas P., Pugsley J.A., and Stewart J.H. Theophylline and salbutamol improve pulmonary function in patients with irreversible chronic obstructive pulmonary disease. Chest 101 (1992) 160-165
18. Nishimura K., Koyama H., Ikeda A., and Izumi T. Is oral theophylline effective in combination with both inhaled anticholinergic agent inhaled β2-agonist in the treatment of stable COPD?. Chest 104 (1993) 179-184
19. Karpel J.P., Kotch A., Zinny M., Pesin J., and Alleyne W. A comparison of inhaled ipratropium, oral theophylline plus inhaled β-agonist, and the combination of all three in patients with COPD. Chest 105 (1994) 1089-1094
20. Nishimura K., Koyama H., Ikeda A., Sugiura N., Kawakatsu K., and Izumi T. The additive effect of theophylline on a high-dose combination of inhaled salbutamol and ipratropium bromide in stable COPD. Chest 107 (1995) 718-723
21. Lefcoe N.M., Toogood J.H., Blennerhassett G., Baskerville J., and Paterson N.A. The addition of an aerosol anticholinergic to an oral beta agonist plus theophylline in asthma and bronchitis: a double-blind single dose study. Chest 82 3 (1982) 300-305
22. Yildiz F., Basyigit I., Yildirim E., Boyaci H., and Ilgazli A. Different bronchodilator combinations have similar effects on health status in COPD. Pulm Pharmacol Ther 19 (2006) 101-106
23. Hanaoka Y., Teramoto S., Yamamoto H., Yamaguchi Y., and Ouchi Y. Effects of the sustained release of theophylline, UnifilR, and tiotropium bromide on pulmonary function and exercise performance in patients with stable chronic obstructive pulmonary disease [abstract]. Proc Am Thorac Soc 3 (2006) A114
24. Freiman J.A., Chalmers T.C., Smith H., and Kuebler R.R. The importance of β, the type II error, and sample size in the design and interpretation of the randomized controlled trial. In: Bailar J.C., and Mosteller F. (Eds). Medical uses of statistics (1992), NEJM Books, Boston, USA 357-373
25. Ram F.S., Jardin J.R., Atallah A., Castro A.A., Mazzini R., Goldstein R., et al. Efficacy of theophylline in people with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir Med 99 (2005) 135-144
26. Sullivan P., Bekir S., Jaffar Z., Page C., Jeffery P., and Costello J. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 343 (1994) 1006-1008
27. Boswell-Smith V., Cazzola M., and Page C.P. Are phosphodiesterase 4 inhibitors just more theophylline?. J Allergy Clin Immunol 117 (2006) 1237-1243